Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
2001 2
2005 1
2016 2
2017 1
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, Herrera-Ramos E, Ruíz-Hernández J, Borderías L, Horcajada J, González-Quevedo N, Rajas O, Briones M, Rodríguez de Castro F, Rodríguez Gallego C, Esen F, Orhun G, Ergin Ozcan P, Senturk E, Ugur Yilmaz C, Orhan N, Arican N, Kaya M, Kucukerden M, Giris M, Akcan U, Bilgic Gazioglu S, Tuzun E, Riff R, Naamani O, Douvdevani A, Takegawa R, Yoshida H, Hirose T, Yamamoto N, Hagiya H, Ojima M, Akeda Y, Tasaki O, Tomono K, Shimazu T, Ono S, Kubo T, Suda S, Ueno T, Ikeda T, Hirose T, Ogura H, Takahashi H, Ojima M, Kang J, Nakamura Y, Kojima T, Shimazu T, Ikeda T, Suda S, Izutani Y, Ueno T, Ono S, Taniguchi T, O M, Dinter C, Lotz J, Eilers B, Wissmann C, Lott R, Meili MM, Schuetz PS, Hawa H, Sharshir M, Aburageila M, Salahuddin N, Chantziara V, Georgiou S, Tsimogianni A, Alexandropoulos P, Vassi A, Lagiou F, Valta M, Micha G, Chinou E, Michaloudis G, Kodaira A, Ikeda T, Ono S, Ueno T, Suda S, Izutani Y, Imaizumi H, De la Torre-Prados MV, Garcia-De la Torre A, Enguix-Armada A, Puerto-Morlan A, Perez-Valero V, Garcia-Alcantara A, Bolton N, Dudziak J, Bonney S, Tridente A, Nee P, Nicolaes G, Wiewel M, Schultz M, Wildhag… See abstract for full author list ➔ Bateman RM, et al. Among authors: o dwyer m. Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Crit Care. 2016. PMID: 27885969 Free PMC article.
Hon P146 - Terlipressin vs. norepinephrine in the Potential Multiorgan Donor(PMD) F. Righetti, E. Colombaroli, G. Castellano P147 - Echocardiography in the potential heart donor exposed to substitution hormonotherapy F. ...Turan P218 - Results of the live kidney tra …
Hon P146 - Terlipressin vs. norepinephrine in the Potential Multiorgan Donor(PMD) F. Righetti, E. Colombaroli, G. Castellano P147 - E …
Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing.
Gurney M, Kundu S, Pandey S, O'Dwyer M. Gurney M, et al. Among authors: o dwyer m. Front Immunol. 2022 Feb 11;13:802906. doi: 10.3389/fimmu.2022.802906. eCollection 2022. Front Immunol. 2022. PMID: 35222382 Free PMC article. Review.
The profound activating and expansion stimulus provided by feeder cells is integral to current applications of clinical-scale genome engineering approaches in donor-derived, primary NK cells. Herein we explore the complex interactions that exist between feeder cells and bo …
The profound activating and expansion stimulus provided by feeder cells is integral to current applications of clinical-scale genome enginee …
Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M, O'Reilly E, Corcoran S, Brophy S, Krawczyk J, Otto NM, Hermanson DL, Childs RW, Szegezdi E, O'Dwyer ME. Gurney M, et al. Among authors: o dwyer me. Cytotherapy. 2022 Nov;24(11):1087-1094. doi: 10.1016/j.jcyt.2022.07.008. Epub 2022 Aug 29. Cytotherapy. 2022. PMID: 36050244 Free article.
DNA transposons are versatile non-viral gene vectors now being adapted to primary NK cells, representing important tools for research and clinical product development. AIMS AND METHODS: We set out to generate donor-derived, primary chimeric antigen receptor (CAR)-NK cells …
DNA transposons are versatile non-viral gene vectors now being adapted to primary NK cells, representing important tools for research and cl …
Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.
Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM. Glavey SV, et al. Among authors: o dwyer me. Leukemia. 2017 Nov;31(11):2426-2434. doi: 10.1038/leu.2017.102. Epub 2017 Mar 27. Leukemia. 2017. PMID: 28344315
We have applied a novel proteomic-based strategy and defined the BM ECM composition in patients with monoclonal gammopathy of undetermined significance (MGUS), newly diagnosed and relapsed MM compared with healthy donor-derived BM ECM. In this study, we show that the tumor …
We have applied a novel proteomic-based strategy and defined the BM ECM composition in patients with monoclonal gammopathy of undetermined s …
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M, Stikvoort A, Nolan E, Kirkham-McCarthy L, Khoruzhenko S, Shivakumar R, Zweegman S, Van de Donk NWCJ, Mutis T, Szegezdi E, Sarkar S, O'Dwyer M. Gurney M, et al. Among authors: o dwyer m. Haematologica. 2022 Feb 1;107(2):437-445. doi: 10.3324/haematol.2020.271908. Haematologica. 2022. PMID: 33375774 Free PMC article.
We set out to develop a CD38 CAR-NK cell therapy for AML, first by using an NK cell line which has low baseline CD38 expression and subsequently healthy donor expanded NK cells. To overcome anticipated fratricide due to NK cell CD38 expression when using primary expanded N …
We set out to develop a CD38 CAR-NK cell therapy for AML, first by using an NK cell line which has low baseline CD38 expression and subseque …
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.
Stikvoort A, van der Schans J, Sarkar S, Poels R, Ruiter R, Naik J, Yuan H, de Bruijn JD, van de Donk NWCJ, Zweegman S, Themeli M, Groen R, O'Dwyer M, Mutis T. Stikvoort A, et al. Among authors: o dwyer m. Hemasphere. 2021 Jun 12;5(7):e596. doi: 10.1097/HS9.0000000000000596. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34131635 Free PMC article.
We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with little or no toxicities against nonmalignant hematopoietic cells. The lack of universal donors and long manufacturing times however limit the broad applic …
We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with little or no toxiciti …
Unchanging attitudes to autologous transfusion in the UK.
Torella F, Haynes SL, Lardi A, O'Dwyer ST, McCollum CN. Torella F, et al. Among authors: o dwyer st. Transfus Med. 2001 Feb;11(1):15-9. doi: 10.1046/j.1365-3148.2001.00284.x. Transfus Med. 2001. PMID: 11328567
Experience of autologous blood transfusion in an obstetrics and gynaecology department.
O'Dwyer G, Mylotte M, Sweeney M, Egan EL. O'Dwyer G, et al. Br J Obstet Gynaecol. 1993 Jun;100(6):571-4. doi: 10.1111/j.1471-0528.1993.tb15311.x. Br J Obstet Gynaecol. 1993. PMID: 8334094
RESULTS: In the abdominal hysterectomy group 329 units of blood were collected of which 48% were transfused to the donors. In the repair group 82 units of blood were collected of which 21.9% were transfused to the donors. In the elective caesarian section group 105 …
RESULTS: In the abdominal hysterectomy group 329 units of blood were collected of which 48% were transfused to the donors. In the rep …
Panel 2.4: funding policies and practices.
Procacci P, Mookejee A, German T, O'Dwyer M, Eppel G. Procacci P, et al. Among authors: o dwyer m. Prehosp Disaster Med. 2005 Nov-Dec;20(6):408-11. doi: 10.1017/s1049023x00002995. Prehosp Disaster Med. 2005. PMID: 16496624
It is presented in the following major sections: (1) issues from the perspectives of (a) donors, and (b) recipients; (2) coordination; (3) conclusions; (4) the size of the response; (5) measuring the Consolidated Appeals Process (CAP) as a financial instrument; (6) other i …
It is presented in the following major sections: (1) issues from the perspectives of (a) donors, and (b) recipients; (2) coordination …
12 results